Although this worthy milestone conveys the excitement and promise of this novel form of cancer treatment, PD-1/PD-L1 blockade therapy in cancer is currently not satisfactory due to the limited response rates (20%–40%; refs. 3–5). Here, PDCD1 is linked to cancer.